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Sir,
We would like to thank Gianluigi Ferreti and his colleagues for
their interest in our systematic review.
In their letter, Ferreti et al. interrogated on the prognostic
role of Ras in NSCLC. They cited seven studies with apparent
conflicting results. Some comments have to be made. First,
we discussed in our articles the controversial results of the
literature relative to biological prognostic factors, justifying the
need for meta-analyses, as we reported with K-Ras (Mascaux et al,
2005) and other biomarkers previously such as p53, bcl2, VEGF,
Neu, Ki-67 or EGFR.
Secondly, we have some concerns with the studies cited by
Ferreti et al. Some of these articles were not included in our
systematic review for the following reasons:
 no prognostic analysis (Ferretti et al, 2000);
 no survival prognostic analysis but assessment of the predictive
role of K-Ras for response to chemotherapy (Eberhard et al,
2005; Winton et al, 2005);
 assessment of K-Ras mutation on resected tumours after
induction chemotherapy (Broermann et al, 2002);
 publication after the deadline for the selection of
the studies to be included in the meta-analysis (Zhu et al,
2004).
The last two studies that Ferreti et al commented (Moldvay et al,
2000; Schiller et al, 2001) were included in our systematic review
and were aggregated with the 26 other evaluable studies for meta-
analysis.
In conclusion, our systematic review showed that K-Ras
is a potential prognostic factor for survival in lung cancer
according to the literature published on this topic till
end of 2003. The predictive role of K-Ras for response to
chemotherapy and the impact of K-Ras mutation on survival
in patients receiving induction chemotherapy before surgery
were not the subjects of our meta-analysis and need further
investigations.
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